What is Leerink Partnrs’ Forecast for ALDX Q1 Earnings?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Stock analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Aldeyra Therapeutics in a research report issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman expects that the biotechnology company will earn ($0.27) per share for the quarter. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.92) per share. Leerink Partnrs also issued estimates for Aldeyra Therapeutics’ Q3 2025 earnings at ($0.17) EPS, FY2025 earnings at ($1.00) EPS, FY2026 earnings at ($1.70) EPS, FY2027 earnings at ($0.45) EPS and FY2028 earnings at $0.75 EPS.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Thursday, March 6th. The biotechnology company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.30).

ALDX has been the topic of several other reports. BTIG Research reduced their target price on Aldeyra Therapeutics from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, April 7th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Aldeyra Therapeutics in a report on Friday, April 4th.

Aldeyra Therapeutics Stock Performance

Shares of ALDX stock opened at $2.01 on Wednesday. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18. The company has a market cap of $120.02 million, a PE ratio of -2.14 and a beta of 0.94. Aldeyra Therapeutics has a 12-month low of $1.14 and a 12-month high of $7.20. The business’s fifty day simple moving average is $5.31 and its 200-day simple moving average is $5.20.

Hedge Funds Weigh In On Aldeyra Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Aldeyra Therapeutics in the first quarter worth $63,000. Woodstock Corp boosted its holdings in Aldeyra Therapeutics by 14.5% in the first quarter. Woodstock Corp now owns 223,094 shares of the biotechnology company’s stock valued at $1,283,000 after purchasing an additional 28,175 shares during the last quarter. Mackenzie Financial Corp grew its position in Aldeyra Therapeutics by 310.9% during the 4th quarter. Mackenzie Financial Corp now owns 47,792 shares of the biotechnology company’s stock worth $238,000 after purchasing an additional 36,160 shares during the period. ProShare Advisors LLC purchased a new position in shares of Aldeyra Therapeutics during the 4th quarter valued at about $70,000. Finally, Millennium Management LLC acquired a new position in shares of Aldeyra Therapeutics in the 4th quarter valued at about $808,000. 59.71% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Aldeyra Therapeutics

In related news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the company’s stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $1.42, for a total value of $4,828,000.00. Following the sale, the insider now owns 5,875,851 shares in the company, valued at $8,343,708.42. This represents a 36.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 8.50% of the stock is owned by insiders.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.